# US 2025/0084088 A1 · Antiviral compounds and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084088 A1
- Document ID: US20250084088A1
- Status: Published application
- Kind: A1
- Application number: 18/816,988
- Filed: 2024-08-27
- Published: 2025-03-13
- Earliest claimed: 2023-08-31
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Deeba Ensan; Rao V. Kalla; Dustin S. Siegel
- Web page: https://patentgrep.com/patent/US20250084088A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 31/14: for RNA viruses
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Antiviral compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-6 alkyl, or —OC2H5;
R2 is C1-6 alkyl, or —OC2H5;
R3 is C1-6 alkyl optionally substituted with —OCOR3a;
R3a is C1-6 alkyl optionally substituted with —NR4aR4b; and
R4a and R4b are each independently H or C1-6 alkyl.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is C1-6 alkyl; and R2 is C1-6 alkyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is C1-3 alkyl; and R2 is C1-3 alkyl.

### Claim at position 5

6-7. (canceled)

### Claim 8 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is —OC2H5; and R2 is —OC2H5.

### Claim at position 7

9-13. (canceled)

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is C1-6 alkyl.

### Claim 15 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is —CH3, —C2H5, or —CH(CH3)2.

### Claim at position 10

16-21. (canceled)

### Claim 22

A compound having the structure
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The compound of claim 22, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 22)

The compound of claim 22, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 22)

The compound of claim 22, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 22)

The compound of claim 22, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 22)

The compound of claim 22, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 22)

The compound of claim 22, having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

A method of treating or preventing a viral infection in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 32 (depends on 31)

The method of claim 31, wherein the viral infection is Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, or Orthomyxovirus virus infection.

### Claim 33

(canceled)

### Claim 34 (depends on 31)

The method of claim 31, wherein the viral infection is human metapneumoavirus (hMPV).

### Claim 35 (depends on 31)

The method of claim 31, wherein the viral infection is respiratory syncytial virus infection.

### Claim 36

(canceled)

### Claim 37 (depends on 31)

The method of claim 31, wherein the viral infection is Human rhinovirus (HRV).

### Claim 38

(canceled)

### Claim 39 (depends on 1)

Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of a viral infection in a human in need thereof.
